Vaxart, Inc.
Close on Oct 19, 2026
- Market cap
- $115.15M
- P/E (TTM)
- 3.2
- Dividend yield
- –
About Vaxart
Biological Products, (No Diagnostic Substances), SIC 2836
Vaxart, Inc. is a clinical-stage biotechnology company that develops oral recombinant vaccines in tablet form using its proprietary Vector-Adjuvant-Antigen Standardized Technology platform. Its product pipeline includes prophylactic vaccine candidates designed to protect against infectious diseases such as norovirus, coronavirus, and seasonal and avian influenza. Additionally, the company is advancing preclinical therapeutic vaccine candidates targeting human papillomavirus-related cervical cancer and dysplasia. Vaxart designs its enteric-coated tablet candidates for broad populations, including adults, children, and infants via passive maternal transfer, and partners with organizations like the Bill & Melinda Gates Foundation and governmental agencies such as BARDA.
The company conducts clinical development activities primarily in the United States, including multi-center trials and human challenge studies across diverse adult participant cohorts. While originally incorporated in California and Delaware, the company operates as a combined entity with clinical programs evaluated nationwide; specific corporate headquarters details are not stated in the text.
Summary of the business section of Vaxart's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Vaxart, Inc.
- Founded
- 2004
- Headquarters
- South San Francisco, CA
- Address
- 310 Utah Avenue, Suite 150
- Phone
- (650) 550-3500
- Website
- vaxart.com
- Employees
- 65, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, San Francisco, California
Stock & identifiers
- Ticker
- VXRT
- Exchange
- OTC
- Shares outstanding
- 243M, Jul 31, 2026
- Public float
- $102.71M, Jun 30, 2025
- Filer category
- Accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-11 reverse, Feb 14, 2018; 1-for-6 reverse, Nov 9, 2012
- SEC CIK
- 72444
- CUSIP
- 92243A200
- ISIN
- US92243A2006
- EIN
- 59-1212264
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Steven Lo | President, Chief Exec Officer, Director | 2,585,606 |
| Jeroen Nicolaas Grasman | Chief Financial Officer | 545,605 |
| Sean Tucker | SVP, Chief Scientific Officer | 943,336 |
| James F. Cummings | Chief Medical Officer | 924,177 |
| Edward B. Berg | SVP, General Counsel | 755,368 |
| Phillip E. Lee | Chief Financial Officer | 631,619 |
| Kevin Finney | Director | 244,171 |
| James B. Breitmeyer | Director | 87,115 |
| David E. Wheadon | Director | 86,150 |
| Elaine J. Heron | Director | 135,966 |
| W. Mark Watson | Director | 173,525 |
| Michael J. Finney | Director | 702,840 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 | $2.09M | $1.48M | $1.18M | $12 | – |
| FY2024 Former PEOOne | $1.93M | $229.97K | $1.18M | $12 | – |
| FY2024 Former PEOTwo | $305.39K | $302.60K | $1.18M | $12 | – |
| FY2023 | $0 | $0 | $1.16M | $10 | – |
| FY2023 Former PEOOne | $1.87M | $1.39M | $1.16M | $10 | – |
| FY2023 Former PEOTwo | $0 | $0 | $1.16M | $10 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 65 full-time equivalent employees, excluding interns.”
Corporate history
Events identified from SEC filings